Trial · NCT03232281
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12 | Triptorelin Pamoate PR 3-month | 98.6 | 95% Confidence Interval 96.65 to 100.00 | percentage of subjects | |
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12 | Triptorelin Acetate PR 1-month | 99.3 | 95% Confidence Interval 97.98 to 100.00 | percentage of subjects | |
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Weeks 4 and 8 | Triptorelin Pamoate PR 3-month | Week 4 | 98.0 | 95% Confidence Interval 95.67 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Weeks 4 and 8 | Triptorelin Acetate PR 1-month | Week 4 | 99.3 | 95% Confidence Interval 98.03 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Weeks 4 and 8 | Triptorelin Pamoate PR 3-month | Week 8 | 97.3 | 95% Confidence Interval 94.65 to 99.91 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Weeks 4 and 8 | Triptorelin Acetate PR 1-month | Week 8 | 100.0 | 95% Confidence Interval 100.00 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 4 | 98.0 | 95% Confidence Interval 95.67 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 4 | 99.3 | 95% Confidence Interval 98.03 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 8 | 95.2 | 95% Confidence Interval 91.80 to 98.68 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 8 | 99.3 | 95% Confidence Interval 98.03 to 100.00 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 12 | 95.9 | 95% Confidence Interval 92.72 to 99.12 | percentage of subjects |
| Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 12 | 98.7 | 95% Confidence Interval 96.83 to 100.00 | percentage of subjects |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 4 | -24.4 | 95% Confidence Interval -27.2 to -21.6 | mm |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 4 | -24.4 | 95% Confidence Interval -27.1 to -21.6 | mm |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 8 | -28.5 | 95% Confidence Interval -31.1 to -25.9 | mm |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 8 | -27.8 | 95% Confidence Interval -30.3 to -25.2 | mm |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Week 12 | -28.1 | 95% Confidence Interval -30.6 to -25.7 | mm |
| Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12 | Triptorelin Acetate PR 1-month | Week 12 | -28.4 | 95% Confidence Interval -30.8 to -26.0 | mm |
| Mean E2 Concentration at Weeks Baseline and 4, 8 and 12 | Triptorelin Pamoate PR 3-month | Baseline | 192.302 | Standard Deviation 258.209 | pmol/L |
| Mean E2 Concentration at Weeks Baseline and 4, 8 and 12 | Triptorelin Acetate PR 1-month | Baseline | 218.893 | Standard Deviation 296.825 | pmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03232281/results